Robert W. Baird upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a neutral rating to an outperform rating in a report issued on Wednesday, October 25th, Marketbeat Ratings reports. Robert W. Baird currently has $228.00 target price on the life sciences company’s stock, up from their prior target price of $184.00.
Several other brokerages have also issued reports on ILMN. Deutsche Bank AG set a $175.00 price objective on Illumina and gave the stock a hold rating in a report on Friday, July 28th. Canaccord Genuity upgraded Illumina from a hold rating to a buy rating and raised their target price for the company from $170.00 to $215.00 in a report on Monday, August 7th. Morgan Stanley restated an underweight rating and set a $122.00 target price (up from $115.00) on shares of Illumina in a report on Monday, July 10th. Barclays PLC reaffirmed a hold rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, July 19th. Finally, Vetr downgraded Illumina from a strong-buy rating to a hold rating and set a $202.18 price target on the stock. in a research report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $200.88.
Illumina (NASDAQ:ILMN) opened at $208.94 on Wednesday. The stock has a market capitalization of $30,505.24, a price-to-earnings ratio of 61.09, a price-to-earnings-growth ratio of 3.45 and a beta of 0.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina has a one year low of $119.37 and a one year high of $214.50.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company’s revenue was up 17.6% compared to the same quarter last year. During the same period last year, the company posted $0.97 EPS. equities research analysts predict that Illumina will post 3.75 earnings per share for the current year.
WARNING: “Illumina, Inc. (NASDAQ:ILMN) Upgraded to Outperform at Robert W. Baird” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/robert-w-baird-upgrades-illumina-inc-ilmn-to-outperform.html.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $194.73, for a total transaction of $3,894,600.00. Following the sale, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $104,993,742.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total transaction of $29,827.95. The disclosure for this sale can be found here. Insiders sold a total of 187,964 shares of company stock valued at $38,454,069 in the last three months. 1.60% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the business. Advisory Services Network LLC raised its stake in shares of Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the last quarter. Penserra Capital Management LLC raised its stake in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the last quarter. Dupont Capital Management Corp bought a new position in Illumina during the third quarter worth $153,000. Paradigm Asset Management Co. LLC raised its stake in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. Finally, Patten Group Inc. raised its stake in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 93.07% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.